2-(3-methylphenyl)-2-adamantanemethanamine | 287173-08-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-methylphenyl)-2-adamantanemethanamine
• 英文别名: [2-(3-Methylphenyl)-2-adamantyl]methanamine
• CAS: 287173-08-4
• 化学式: C₁₈H₂₅N
• 分子量: 255.403
• InChiKey: UOQAPRSNEKTPDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Pharmaceutical composition effective in treatment of mechanical allodynia, screening method of potential compound as said pharmaceutical composition, inspection method of mechanical allodynia, and treatment method of mechanical allodynia
  申请人：——

  公开号：US20040254148A1

  公开（公告）日：2004-12-16

  The present invention aims to identify the molecule involved in mechanical allodynia, and to develop and provide a pharmaceutical composition to target this molecule such that the composition is effective in the treatment of mechanical allodynia. The present invention also aims to provide a screening method for compounds for use in such pharmaceutical compositions, a method of determining mechanical allodynia, and a treatment method of mechanical allodynia.

  本发明旨在确定参与机械异感症的分子，并开发和提供一种针对该分子的药物组合物，从而使该组合物能够有效治疗机械异感症。本发明还旨在提供一种用于此类药物组合物的化合物筛选方法、一种确定机械性异感症的方法以及一种治疗机械性异感症的方法。
• 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1143964A1

  公开（公告）日：2001-10-17
• JP2002535360A
  申请人：——

  公开号：JP2002535360A

  公开（公告）日：2002-10-22
• US6531511B1
  申请人：——

  公开号：US6531511B1

  公开（公告）日：2003-03-11
• [EN] 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION<br/>[FR] COMPOSES DE 2-ADAMANTANEMETHANAMINE DESTINES AU TRAITEMENT D'ANOMALIES DE LA TRANSMISSION GLUTAMATERGIQUE
  申请人：VERNALIS RESEARCH LIMITED

  公开号：WO2000044371A1

  公开（公告）日：2000-08-03

  The use of a compound of formula (1), wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wherein R1 to R4 and R6 are hydrogen, R5 is not selected from CH2CH2NHSO2CH3, CH2CH2NHSO2CF3 and methyl substituted by SO2NH2, SO3H, PO3H2, CONHOH or a heterocyclic group selected from formulae (a), (b), (c), (d) and (e) in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.